Autoimmune

Immunovant's IMVT-1402 Shows Blockbuster Potential in Autoimmune Disease; Wave Life Sciences Advances RNA Editing

Immunovant's IMVT-1402 demonstrates significant promise in treating difficult-to-treat rheumatoid arthritis, positioning it as a potential blockbuster. Concurrently, Wave Life Sciences is making strides in RNA editing for rare diseases, highlighting innovation in genetic medicine.

Rallybio Pursues Reverse Merger with Avenzo Therapeutics to Advance Autoimmune Pipeline

Rallybio is attempting a reverse merger with Avenzo Therapeutics, a move that will see the combined entity focus on Avenzo's T-cell engager pipeline for autoimmune diseases. The transaction includes a substantial concurrent financing round.

UCB Acquires Antibody Treatment Maker: Implications for Autoimmune Disease Market

UCB's recent acquisition of a company specializing in antibody treatments for autoimmune diseases could reshape the competitive landscape. This article explores the implications for investors and pharma teams.

UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal

UCB's acquisition of Candid Therapeutics strengthens autoimmune pipeline as Two River and Vida Ventures celebrate successful exit from clinical-stage biotech.

FDA Grants Priority Review for IMAAVY (Nipocalimab-aahu) as First Potential Treatment for Warm Autoimmune Hemolytic Anemia

FDA grants Priority Review for IMAAVY (nipocalimab-aahu), potentially the first approved treatment for warm autoimmune hemolytic anemia (wAIHA).

Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment

Nkarta secures FDA agreement for outpatient NKX019 dosing, expanding access to community rheumatology centers and reducing patient treatment burden.